{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:49:11Z","timestamp":1791560951667,"version":"4.3.4"},"reference-count":20,"publisher":"Bioscientifica","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate the activity and tolerability of the CAPTEM regimen (capecitabine + temozolomide) in patients with advanced, heavily pretreated adrenocortical carcinoma (ACC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective analysis of 15 patients with metastatic ACC who received at least two lines of systemic therapy, including the CAPTEM regimen, between 2017 and 2022. Clinical characteristics, treatment outcomes (PFS and OS), and toxicities were collected and analysed. Treatment response was assessed using the RECIST 1.1 criteria. Survival outcomes were estimated using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 15 patients, CAPTEM was administered in the first-line therapy in three patients (20%), in the second-line therapy in eight patients (53.3%), and in further lines in the remaining cases. The overall disease control rate was 26.6% (all stable disease). The median progression-free survival (PFS) was 3 months (95% CI: 2\u20136), and the median overall survival (OS) was 8 months (95% CI: 6\u201313). Patients who achieved disease stabilization had improved outcomes (mPFS: 9.5 months; mOS: 16.5 months) compared with those with progression (mPFS: 2 months; mOS: 7 months). Treatment-related adverse events occurred in 86.7% of patients, mostly mild; grade 3 toxicity was observed in one patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CAPTEM regimen demonstrated modest activity and acceptable toxicity in a heavily pretreated ACC population. While not recommended as a standard treatment, CAPTEM may be considered in select patients, particularly those who achieve disease stabilization. Further prospective studies are needed to better define its role and identify predictive biomarkers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-26-0136","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:24:38Z","timestamp":1790169878000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of the CAPTEM regimen in patients with advanced adrenocortical carcinoma"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3087-8303","authenticated-orcid":true,"given":"Barbara","family":"Zi\u00f3\u0142kowska","sequence":"first","affiliation":[{"name":"2nd Department of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch 1 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8086-7346","authenticated-orcid":true,"given":"Agnieszka","family":"Kotecka-Blicharz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology 2 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Handkiewicz-Junak","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology 2 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"Hasse-Lazar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology 2 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Gawlik","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology 2 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Idasiak","sequence":"additional","affiliation":[{"name":"2nd Department of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch 1 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Krzywon","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch 3 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Suwi\u0144ski","sequence":"additional","affiliation":[{"name":"2nd Department of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch 1 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026100910560928800_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40618-013-0049-2","article-title":"Management of adrenal cancer: a 2013 update","volume":"37","author":"Terzolo","year":"2014","journal-title":"J Endocrinol Investig"},{"key":"2026100910560928800_bib2","first-page":"1","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"BioMed Res Int"},{"key":"2026100910560928800_bib3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026100910560928800_bib4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"2026100910560928800_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as second-\/third-line chemotherapy in advanced adrenocortical carcinoma","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2026100910560928800_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"2026100910560928800_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026100910560928800_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026100910560928800_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.022","article-title":"An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma","volume":"33","author":"Campbell","year":"2022","journal-title":"Ann Oncol"},{"key":"2026100910560928800_bib10","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.2147\/CMAR.S372776","article-title":"Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms: a systematic review and pooled analysis","volume":"14","author":"Arrivi","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2026100910560928800_bib11","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1210\/jc.2016-2768","article-title":"Inhibition of human adrenocortical cancer cell growth by temozolomide in vitro and the role of the MGMT gene","volume":"101","author":"Creemers","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100910560928800_bib12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2026100910560928800_bib13","first-page":"1461","article-title":"Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity","volume":"17","author":"Murakami","year":"2007","journal-title":"Oncol Rep"},{"key":"2026100910560928800_bib14","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100910560928800_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/iju5.12214","article-title":"Advanced adrenocortical carcinoma treated with gemcitabine plus capecitabine","volume":"3","author":"Yamamoto","year":"2020","journal-title":"IJU Case Rep"},{"key":"2026100910560928800_bib16","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100910560928800_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.624102","article-title":"Prognostic factors in patients with metastatic ACC treated with gemcitabine plus capecitabine","volume":"12","author":"Grisanti","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026100910560928800_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12672-020-00385-3","article-title":"Advanced adrenocortical carcinoma (ACC): a review with focus on second-line therapies","volume":"11","author":"Ardolino","year":"2020","journal-title":"Horm Cancer"},{"key":"2026100910560928800_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.674039","article-title":"Exceptional response to second line temozolomide therapy in metastatic ACC","volume":"12","author":"Cosentini","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026100910560928800_bib20","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and disease control of advanced ACC with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0136\/525647\/ec-26-0136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0136\/525647\/ec-26-0136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:56:13Z","timestamp":1791557773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/10\/e260136\/78253\/Efficacy-and-safety-of-the-CAPTEM-regimen-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-26-0136","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"e260136"}}